|

Azirkitug Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: ABBV-514

Pipeline

Phase 1: 1

Top Sponsors

  • AbbVie1

Indications

  • Gastric/Esophageal Cancer1
  • Micro Satellite Stable Colorectal Cancer1
  • High-grade Serous Ovarian Cancer1
  • Triple Negative Breast Cancer1
  • Pancreatic Cancer1

Duarte, California1 trial

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

City of Hope National Medical Center /ID# 276272

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.